905587-44-2

Usage

Uses

Used in Pharmaceutical Industry:
1-(5-fluoropyrimidin-2-yl)ethanone is used as a chemical intermediate for the synthesis of various pharmaceutical compounds, leveraging its pyrimidine structure for the development of antiviral or anticancer drugs. The presence of the fluorine atom at the 5-position of the pyrimidine ring may enhance the compound's pharmacological properties, making it a promising candidate for further research and development in medicinal chemistry.
Used in Antiviral Drug Development:
1-(5-fluoropyrimidin-2-yl)ethanone is used as a key component in the design and synthesis of antiviral agents, where its pyrimidine structure can potentially interfere with viral replication mechanisms. The fluorination at the 5-position may contribute to improved antiviral activity and selectivity, offering a novel approach to combat viral infections.
Used in Anticancer Drug Development:
1-(5-fluoropyrimidin-2-yl)ethanone is utilized as a building block in the creation of anticancer drugs, with its pyrimidine framework playing a crucial role in targeting cancer cells. The incorporation of the fluorine atom may enhance the compound's ability to inhibit cancer cell growth and proliferation, providing a new avenue for cancer treatment.

Upstream product

• 75-16-1 methylmagnesium bromide 
• 38275-55-7 5- fluoropyrimidine-2-carbonitrile 
• 676-58-4 methylmagnesium chloride 

Downstream Products

• 905587-30-6 (S)-tert-butyl-1-(5-fluoropyrimidin-2-yl)ethylcarbamate 
• 935666-88-9 AZD1480 
• 935667-21-3 (1S)-1-(5-fluoropyrimidin-2-yl)ethanamine monohydrochloride 
• 1429182-93-3 1-(5-(4-fluorophenoxy)pyrimidin-2-yl)ethanamine 
• 1429182-18-2 1-(5-(4-fluorophenoxy)pyrimidin-2-yl)ethanone 
• 905587-41-9 1-(5-fluoropyrimidin-2-yl)ethanamine 
• 905587-43-1 1-(5-fluoropyrimidin-2-yl)ethan-1-ol 

Relevant academic research and scientific papers

Use of ω-transaminase enzyme chemistry in the synthesis of a JAK2 kinase inhibitor

ω-Transaminase enzyme chemistry provides an excellent methodology to build synthetically useful chiral amines from their corresponding ketones. An application of this methodology, providing a long-term commercial manufacturing route to a JAK2 kinase inhibitor, is reported herein.

Discovery of 5-chloro- N 2-[(1 S)-1-(5-fluoropyrimidin-2-yl) ethyl]- N 4-(5-methyl-1 H -pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the jak/stat pathway

The myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis are a heterogeneous but related group of hematological malignancies characterized by clonal expansion of one or more myeloid lineages. The discovery of the Jak2 V617F gain of function mutation highlighted Jak2 as a potential therapeutic target in the MPNs. Herein, we disclose the discovery of a series of pyrazol-3-yl pyrimidin-4-amines and the identification of 9e (AZD1480) as a potent Jak2 inhibitor. 9e inhibits signaling and proliferation of Jak2 V617F cell lines in vitro, demonstrates in vivo efficacy in a TEL-Jak2 model, has excellent physical properties and preclinical pharmacokinetics, and is currently being evaluated in Phase I clinical trials.

The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis

Two series of N-hydroxyformamide inhibitors of ADAM-TS4 were identified from screening compounds previously synthesised as inhibitors of matrix metalloproteinase-13 (collagenase-3). Understanding of the binding mode of this class of compound using ADAM-TS1 as a structural surrogate has led to the discovery of potent and very selective inhibitors with favourable DMPK properties. Synthesis, structure-activity relationships, and strategies to improve selectivity and lower in vivo metabolic clearance are described.

CHEMICAL COMPOUNDS 916-1

The present invention relates to compounds of Formula (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer.

PYRAZOLYL-AMINO-SUBSTITUTED PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CANCER

The present invention relates to compounds of Formula (I) and to their pharmaceutical compositions, and to their methods of use. These compounds provide a treatment for myeloproliferative disorders and cancer.

4- (3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER

This invention relates to novel compounds having the formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.

PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS

This invention relates to novel compounds having the Formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.